WONDERLAB Joins Leading Experts at the HeartGut Conference, Advancing Evidence-Based Clinical Research for Probiotics

On the 20th World Gut Health Day, the 2024 HeartGut Conference was held in Wuhan. The event was organized by the HeartGut Research Institute, Wuhan Polytechnic University and the international academic journal iMeta. On May 30, WONDERLAB and the HeartGut Research Institute co-hosted the conference’s Evidence-Based Probiotic Research Forum, bringing together experts to discuss gut mechanisms, clinical research and the development of the probiotic industry.

At the forum, Jing Yuan, a microbiology professor and doctoral supervisor at Peking University, a doctoral supervisor at Peking Union Medical College and deputy director and researcher at the Capital Institute of Pediatrics, delivered remarks. Shuangjiang Liu, president of the Gut Microbiota Branch of the Chinese Biophysical Society and former director of the Institute of Microbiology, Chinese Academy of Sciences, and Xiaoyang Sheng, deputy chair of the Maternal and Child Nutrition Branch of the Chinese Nutrition Society and chief physician at the Developmental and Behavioral Child Health Department of Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, also shared their expertise. They discussed probiotic mechanisms in the gut and clinical research findings with nearly 100 researchers, media representatives and consumers. Xinhua Net participated throughout as a media-support partner.

2024 HeartGut Conference venue

Leading Experts Gather to Discuss Evidence-Based Probiotic Research

In her opening remarks, Professor Jing Yuan said: “Scientific evidence for probiotics is extremely important and meaningful. It is not enough to conduct research; it must be deep and rigorous. Product benefits must be supported by scientific evidence, and the entire production chain must also be evidence-based.”

Professor Jing Yuan delivers opening remarks

Professor Shuangjiang Liu, president of the Gut Microbiota Branch of the Chinese Biophysical Society and former director of the Institute of Microbiology, Chinese Academy of Sciences, presented “The Gut Health Status of the Chinese Population and the Mechanisms of Probiotic Action in the Gut.” He said that many studies indicate probiotics may improve gastrointestinal health, and that research into gut-microbiota functions and probiotic benefits should follow scientific and evidence-based principles: “Well-established benefits and clear mechanisms are the basic requirements for scientific evidence.”

Professor Shuangjiang Liu shares his research

Flagship Products Present Clinical Findings as WONDERLAB Advances the Probiotic Industry

WONDERLAB has consistently treated scientific evidence as the foundation for the long-term development of the probiotic industry. Product development should be supported by evidence across three dimensions: ingredients, formulation and benefits.

At the forum, WONDERLAB presented evidence-based clinical research on its flagship All-in-One Probiotics (nicknamed “Blue Bottle”). The company explained that, during early development, it conducted extensive technical research into probiotic mechanisms in the gut, drawing on 31 patents in eight countries and 983 professional publications. The research examined how probiotics may affect human health through multiple mechanisms after entering the gut. Product development included in-vitro human screening, animal screening and validation, and human clinical-benefit studies. These screening stages aimed to preserve probiotic viability through fermentation, processing, storage and transport, consumption and colonization, supporting the focus of the strains used in the upgraded formula on gut health.

WONDERLAB presents its evidence-based research pathway

In the human clinical-benefit research on All-in-One Probiotics, investigators evaluated reported effects related to gut health, immune health and weight management among volunteers with functional constipation (FC) and functional diarrhea (FDr). The study reported that after four weeks of continuous use of WONDERLAB “Blue Bottle” probiotics, participants with functional constipation showed improvements in gut health and digestion, greater satisfaction with bowel habits, changes in immune-function measures and improvements in inflammation-related indicators.

Sheng also presented interim findings from a clinical study of another WONDERLAB product, WONDERLAB Kids Ready-to-Eat Probiotics, examining immune-health outcomes in preschool children. The clinical data reported that the probiotic blend was associated with prevention and improvement of upper respiratory tract infections in preschool children, including lower risk and incidence, shorter symptom duration, reduced medication use and fewer absences related to infection. The study also reported support for overall sleep quality, bowel habits and gut-microbiota regulation.

Professor Xiaoyang Sheng speaks at the forum

At the close of the forum, Canhui Lan, president of the HeartGut Institute and co-founder and executive editor-in-chief of iMeta, said he was pleased to see WONDERLAB continuing to advance clinical evidence-based research in China. He also looked forward to the future application of proprietary strains in products and the introduction of evidence-based products developed with Chinese characteristics.

President Canhui Lan delivers remarks

WONDERLAB is currently advancing human clinical-benefit research for several additional products. During the 2024 HeartGut Conference, the HeartGut Institute also named WONDERLAB “Most Influential Adult Probiotic Brand of the Year” in its 2023–2024 Gut Industry List.

WONDERLAB has consistently focused on evidence-based health products and treated probiotic research and application as a long-term commitment. Going forward, it will continue to deepen its work in probiotics, provide high-quality products and health services through a science- and evidence-based R&D philosophy, and explore a path toward high-quality development of the probiotic industry.